Nature Reviews Urology - Table of Contents alert Volume 13 Issue 4

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS
April 2016 Volume 13 Number 4
Impact Factor 4.840 *	In this issue Research Highlights News and Views Reviews Also this month  Featured article: Active surveillance for prostate cancer: current evidence and contemporary state of practice Jeffrey J. Tosoian, H. Ballentine Carter, Abbey Lepor & Stacy Loeb
Subscribe   Facebook   RSS   Recommend to library   Twitter
RESEARCH HIGHLIGHTS Top Prostate cancer: Multilayered mutation analysis indicates divergent clonal evolution Published online: 23 February 2016 p179 | doi:10.1038/nrurol.2016.38 PDF Bladder cancer: Could chemohyperthermia finally set the NMIBC world on fire? Published online: 09 February 2016 p180 | doi:10.1038/nrurol.2016.29 PDF Prostate cancer: The TRAPEZE swings for treatment results Published online: 09 February 2016 p180 | doi:10.1038/nrurol.2016.32 PDF Genetics: Selfish spermatogonia Published online: 23 February 2016 p181 | doi:10.1038/nrurol.2016.37 PDF Paediatrics: Mirabegron for paediatric OAB Published online: 01 March 2016 p181 | doi:10.1038/nrurol.2016.44 PDF Prostate cancer: Proton therapy delays progression Published online: 08 March 2016 p181 | doi:10.1038/nrurol.2016.50 PDF Bladder cancer: Urinary microRNA profiling for predicting UCB recurrence Published online: 16 February 2016 p182 | doi:10.1038/nrurol.2016.36 PDF Development: Adult Leydig cell maintenance Published online: 15 March 2016 p182 | doi:10.1038/nrurol.2016.51 PDF Prostate Cancer: Box clever — YB-1 has a role in CRPC Published online: 23 February 2016 p183 | doi:10.1038/nrurol.2016.43 PDF Surgery: Novel mesh materials tested Published online: 01 March 2016 p184 | doi:10.1038/nrurol.2016.48 PDF Penile cancer: Ongoing search for molecular prognostic markers Published online: 08 March 2016 p184 | doi:10.1038/nrurol.2016.49 PDF IN BRIEF Prostate cancer: Enzalutamide plus docetaxel tested in mCRPC | Prostate cancer: Triple combination therapy tested in mCRPC | Kidney cancer: Naptumomab estafenatox ineffective in RCC | Prostate cancer: Integrin inhibitors active against bone metastases PDF Nature Reviews Urology EVENT The 3rd Friends of Israel Urology Symposium (FOIU) 07.07.16 Tel Aviv, Israel More science events from
NEWS AND VIEWS		Top
Prostate cancer: The applicability of textural analysis of MRI for grading Frederick Kelcz & David F. Jarrard Published online: 16 February 2016 p185 | doi:10.1038/nrurol.2016.33 The ability of computers to derive the Gleason score of a tumour directly from the pixel-to-pixel variations that encompass radiological texture has been shown to be accurate. However, the methodology did not mirror the daily clinical task that radiologists face. Further research is required to validate the applicability of this technique. Full Text | PDF
Prostate cancer: Case volume and improved outcomes across cancer care Amol K. Narang & Phuoc T. Tran Published online: 02 February 2016 p186 | doi:10.1038/nrurol.2016.15 The positive association between hospital case volume and surgical outcomes is well established in cancer care. Recent reports have increasingly indicated that this relationship also applies to other cancer disciplines, including radiation therapy. Characterizing the extent to which cancer centre experience drives oncological outcomes is critical for patient decision making. Full Text | PDF
Prostate cancer: Increased dementia risk following androgen deprivation therapy? Ralph N. Martins & Sam Gandy Published online: 23 February 2016 p188 | doi:10.1038/nrurol.2016.34 Although the increased use of androgen deprivation therapy for prostate cancer might be improving survival, a recent large retrospective cohort study that analysed hospital medical record data indicates that long therapy duration is associated with an increased risk of Alzheimer's disease. Full Text | PDF
Prostate cancer: Testosterone-guided ADT for prostate cancer Tsutomu Nishiyama & Tatsuhiko Hoshii Published online: 27 January 2016 p189 | doi:10.1038/nrurol.2016.9 Luteinizing-hormone-releasing hormone (LHRH) agonists as androgen deprivation therapy (ADT) for men with advanced prostate cancer are usually administered indefinitely on a fixed schedule. However, using testosterone level to guide ADT in these patients could lead to reductions in cost and some symptomatic improvements. Full Text | PDF
REVIEWS		Top
Receptors, channels, and signalling in the urothelial sensory system in the bladder Liana Merrill, Eric J. Gonzalez, Beatrice M. Girard & Margaret A. Vizzard Published online: 01 March 2016 p193 | doi:10.1038/nrurol.2016.13 Micturition requires a complex neural control system to coordinate the activities of the urinary bladder, urethra, and urethral sphincters. The specific identity of the mechanical sensor is not known, but considerable interest exists in the contribution of transient receptor potential channels to the mechanosensory functions of the urothelium. These channels could be novel targets for potential therapies that are intended to modulate micturition function. Abstract | Full Text | PDF
Active surveillance for prostate cancer: current evidence and contemporary state of practice Jeffrey J. Tosoian, H. Ballentine Carter, Abbey Lepor & Stacy Loeb Published online: 08 March 2016 p205 | doi:10.1038/nrurol.2016.45 Active surveillance as a management strategy for favourable-risk prostate cancer has increased in recent years, in an effort to prevent the adverse effects associated with unnecessary overtreatment of low-risk disease. However, long-term data have, in the past, been lacking, making it difficult to assess the effectiveness of this approach. In this Review, Tosoian et al. discuss the current state-of-the-art in active surveillance, reviewing the available evidence and considering future directions in the field. Abstract | Full Text | PDF
Erection rehabilitation following prostatectomy — current strategies and future directions Nikolai A. Sopko & Arthur L. Burnett Published online: 15 March 2016 p216 | doi:10.1038/nrurol.2016.47 In this Review, Sopko and Burnett summarize strategies to mitigate adverse penile remodelling and protect erectile function in men undergoing prostatectomy. They discuss innovations for surgery, the use of phosphodiesterase type 5 inhibitors, intracavernosal injections and vacuum erection devices, as well as possible future treatments. Multidisciplinary approaches are required, but the best therapy scheme has not yet been identified. Abstract | Full Text | PDF
Current use of PSMA-PET in prostate cancer management Tobias Maurer, Matthias Eiber, Markus Schwaiger & Jürgen E. Gschwend Published online: 23 February 2016 p226 | doi:10.1038/nrurol.2016.26 Prostate-specific membrane antigen (PSMA) has gained increasing interest as target molecule for imaging. Several small compounds for labelling PSMA have been developed and are currently being investigated as imaging probes for PET. PSMA-based imaging has been reported to improve detection of metastatic disease compared with CT or multiparametric MRI and 68Ga-PSMA-PET imaging has been shown to increase detection of metastatic sites, therefore, it holds great promise to improve prostate cancer management. Abstract | Full Text | PDF
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*Journal Citation Reports, Thomson, 2015. Nature Reviews Urology was previously published as Nature Clinical Practice Urology.

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.